Amendment to PA-04-074: Health Disparities in NIDDK Diseases
Notice Number:NOT-DK-04-015
Key Dates Release Date: September 2, 2004
Issued by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), (http://www.niddk.nih.gov)The purpose of this Notice is to inform potential applicants of an
amendment to PA-04-074. The information in the section of the program
announcement (PA) titled SUPPLEMENTARY INSTRUCTION states: All application instructions outlined in the PHS 398 application kit
are to be followed, with the following requirements for R21
applications: 1. R21 applications will use the "MODULAR GRANT" and "JUST-IN-TIME"
concepts, with direct costs requested in $25,000 modules, up to the
total direct costs limit of $275,000 for the two year period.
2. Although preliminary data are not required for an R21 application,
they may be included.
3. Sections a-d of the Research Plan of the R21 application may not
exceed 15 pages, including tables and figures.
4. Use the instructions for appendix detailed in the PHS 398 except
that no more than 5 manuscripts, previously accepted for publication,
may be included. Further details regarding the purpose and format of R21 applications
can be found by reading the NINDS guidelines describing the R21 program
(http://www.ninds.nih.gov/funding/r21guidelines.htm). All R21
applications submitted in response to this Program Announcement should
follow the NINDS guidelines, regardless of Institute assignment.
Applicants may also contact one of the Program Officials listed under
"Inquiries" for further information. If there is other important
information it should be included in the PA. R21 applications deemed
not to be responsive to this program announcement will be returned .
The information above has been deleted and does not apply to this PA.
The amended section on SUPPLEMENTARY INSTRUCTIONS now states:
INSTRUCTIONS FOR R21 APPLICATIONS: All applications submitted in
response to this PA for the R21 (Exploratory/Developmental Research
Grant) must adhere to the page and budgetary limitations described in
the trans-NIH R21 program announcement (PA-03-107) available at:
http://grants.nih.gov/grants/guide/pa-files/PA-03-107.html
All other aspects of the PA remain unchanged.
The full text of the PA, which was published March 11, 2004, can be
accessed at the following location:
http://grants.nih.gov/grants/guide/pa-files/PA-04-074.html
Inquires regarding this notice should be directed to:
Myrlene Staten, M.D.
Division of Diabetes, Endocrinology and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 6107
Bethesda, MD 20892-5460
Telephone: (301) 402-7886
FAX: (301) 480-3503
Email: [email protected]
Lawrence Agodoa, M.D.
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 653
Bethesda, MD 20892-5460
Telephone: (301) 594-5454
FAX: (301) 594-9358
Email: [email protected]
Marva Moxey-Mims, M.D.
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 639
Bethesda, MD 20892-5460
Telephone: (301) 451-5037
FAX: (301) 480-3510
Email: [email protected]
Frank Hamilton, M.D.
Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 669
Bethesda, MD 20892-5460
Telephone: (301) 594-8877
FAX: (301) 480-8300
Email: [email protected]
